Pharma BD Deal Intelligence
A $2.5B bet that CoolSculpting would anchor Allergan's third aesthetics pillar instead needed a ~$1.0B impairment within six years, as revenue erosion, the Linda Evangelista disfigurement lawsuit, and a self-inflicted marketing pullback left the franchise never earning back its purchase price.
CoolSculpting fit Allergan's (then AbbVie's) aesthetics strategy but the ~$2.5B asset needed a ~$1.0B write-down within six years of the deal, undercut by early revenue erosion, a high-profile disfigurement lawsuit, and a self-inflicted marketing misstep — a franchise that never earned its purchase price back.
Full analysis, sources & comparables →BioPharma Dive noted the deal would be 'immediately accretive,' citing Zeltiq's $354M FY2016 sales and 17-20% projected 2017 growth. Cited MarketsAndMarkets…
Fortune highlighted the 14.4% premium to prior close and contextualized the deal as part of CEO Brent Saunders's acquisitive playbook following the failed…
BioWorld characterized the deal as portfolio reshaping that adds the FDA-cleared CoolSculpting franchise as the third pillar of Allergan's medical aesthetics…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Allergan agreed to acquire Zeltiq Aesthetics for $56.50/share in cash, total enterprise value approximately $2.47B. The deal added the FDA-cleared CoolSculpting System to Allergan's medical aesthetics platform as a third pillar alongside facial aesthetics and breast/regenerative medicine. Closed April 28, 2017.
CoolSculpting fit Allergan's (then AbbVie's) aesthetics strategy but the ~$2.5B asset needed a ~$1.0B write-down within six years of the deal, undercut by early revenue erosion, a high-profile disfigurement lawsuit, and a self-inflicted marketing misstep — a franchise that never earned its purchase price back.
Assessment window: 5yr post-close.
$13.3B Global medical aesthetics market projection 2021 (MarketsAndMarkets, cited by BioPharma Dive) · $354M Zeltiq FY2016 revenue
Non-invasive body contouring is an elective, cash-pay aesthetic procedure category targeting localized subcutaneous fat without surgery. CoolSculpting uses cryolipolysis — controlled cooling that selectively crystallizes adipocytes for natural clearance — and was the segment leader at deal time. The category sits within medical aesthetics alongside neurotoxins, dermal fillers and energy-based skin treatments.
CoolSculpting was the cash-pay body contouring leader pre-deal, with a $4B opportunity Allergan cited in its rationale and FY2016 Zeltiq revenue of ~$354M. Direct device competitors included Cynosure's SculpSure (laser lipolysis), BTL Industries' Vanquish ME (radio frequency) and Emsculpt (HIFEM muscle stimulation), plus Solta Medical's Liposonix (ultrasound). Allergan's existing aesthetics franchise — Botox (neurotoxin), Juvederm (filler) and Kybella (deoxycholic acid for submental fat) — gave it a captive injector channel to cross-sell device-based body contouring. CEO Brent Saunders argued Kybella and CoolSculpting were complementary not competitive — Kybella for the face, CoolSculpting for the body — with bundled procedure economics. Analysts framed the deal as a defensive move into cash-pay aesthetics at a time of payer pressure on prescription drugs (Credit Suisse), with cross-sell upside (Stifel) but no near-term EPS lift beyond accretion. The deal made body contouring the third pillar of Allergan's aesthetics platform alongside facial aesthetics and breast/regenerative.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Zeltiq Aesthetics, Inc. (this deal) | 2017 | $2.5B | 32 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2017 deals · Allergan plc deals · Other deals